Business
Altimmune to Announce Year End 2019 Financial Results on March 27
GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., March 25, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2019 and host a conference call on Friday, March 27, 2020.\n Conference Call DetailsDate:Friday, March 27Time:8:30 am Eastern TimeDomestic:877-423-9813International:201-689-8573Conference ID:13701071Webcast:http://public.viavid.com/index.php?id=138792 About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com. Contacts: Will BrownAshley R. RobinsonChief Financial OfficerLifeSci Advisors, LLCPhone: [email protected]@lifesciadvisors.com\n\n\nSource: Altimmune, Inc.","length":3473,"tagName":"div"}]